Here are four quick facts about the rating, as reported by Financial Market News.
1. Two equities research analysts gave Accretive Health’s stock a “hold” rating, while another analyst issued a “strong buy” rating on the company.
2. Accretive Health’s rating score has improved by 22.3 percent from three months ago due to numerous analysts’ ratings changes.
3. Analysts have a consensus one-year price target of $4.50 for the company and expect Accretive Health to post $0.08 earnings per share for the current quarter, according to Zacks.
4. The company has a 12-month low of $1.77 and a 12-month high of $6.30.
More articles on finance and revenue cycle management:
For-profit hospital stock report: Week of Feb. 15-19
OIG: Connecticut hospital received $249k in Medicare overpayments
Medicare spending spikes due to lengthy hospice care: 5 things to know
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
